Barbara Weber - 12 Aug 2021 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Executive Officer, Director
Signature
/s/ William Collins, as attorney-in-fact
Issuer symbol
TNGX
Transactions as of
12 Aug 2021
Net transactions value
$0
Form type
4
Filing time
16 Aug 2021, 19:00:31 UTC
Previous filing
12 Aug 2021
Next filing
27 Oct 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +961,403 $0.000000 961,403 12 Aug 2021 Common Stock 961,403 $9.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable over a four-year period, at a rate of 25% on August 10, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.